Claims for Patent: 8,273,712

Summary for Patent: 8,273,712

Title:	Promoting wound healing by administering a prostaglandin E and granulocyte-macrophage colony stimulating factor
Abstract:	A method of promoting healing of a wound in a patient, the method comprising administering to the patient (i) a prostaglandin E (PGE) or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) granulocyte-macrophage colony stimulating factor (GMCSF) or a derivative thereof. Use of (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof in the preparation of a medicament for promoting healing of a wound in a patient. A wound dressing, bandage or fibrin glue comprising (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof.
Inventor(s):	Kelly; Rodney (Edinburgh, GB)
Assignee:	Medical Research Council (Swindon, Wiltshire, GB)
Application Number:	12/094,322
Patent Claims:	1. A method of promoting healing of a wound in a patient, the method comprising administering to the patient, within the first four days following wounding, (i) a prostaglandin E (PGE) or an agonist thereof and (ii) granulocyte-macrophage colony stimulating factor (GMCSF) or a derivative thereof, wherein the method does not include administering a skin stem cell to the patient and said administering is carried out by applying to the wound a wound dressing or bandage that comprises (i) and (ii). 2. A method according to claim 1 wherein the PGE or agonist thereof is any one of PGE.sub.1, PGE.sub.2, 19-hydroxy PGE.sub.1, 19-hydroxy PGE.sub.2, 16,16-dimethyl PGE, dinoprostone, misoprostol, alprostadil and limaprost. 3. A method according to claim 1 wherein the GMCSF is human GMCSF having the amino acid sequence of SEQ ID NO: 2, or a naturally occurring variant thereof. 4. A method according to claim 1 wherein the GMCSF is sargramostim or molgramostim. 5. A method according to claim 1 further comprising administering at least one antimicrobial agent to the patient. 6. A method according to claim 5 wherein the antimicrobial agent is an antibacterial agent, an antifungal agent or an antiviral agent. 7. A method according to claim 6 wherein the antibacterial agent is selected from gentamicin, ampicillin, benzypenicillin, benethamine penicillin, benzathine penicillin, phenethicillin, phenoxy-methyl penicillin, procaine penicillin, cloxacillin, flucloxacillin, methicillin sodium, amoxicillin, bacampicillin hydrochloride, ciclacillin, mezlocillin, pivampicillin, talampicillin hydrochloride, carfecillin sodium, piperacillin, ticarcillin, mecillinam, pirmecillinan, cefaclor, cefadroxil, cefotaxime, cefoxitin, cefsulodin sodium, ceftazidime, ceftizoxime, cefuroxime, cephalexin, cephalothin, cephamandole, cephazolin, cephradine, cefpirome, latamoxef disodium, aztreonam, glycylcyclines, chlortetracycline hydrochloride, clomocycline sodium, demeclocydine hydrochloride, doxycycline, lymecycline, minocycline, oxytetracycline, amikacin, framycetin sulphate, neomycin sulphate, netilmicin, tobramycin, colistin, sodium fusidate, fupirocin, polymyxin B sulphate, spectinomycin, vancomycin, teicoplanin, calcium sulphaloxate, sulphametopyrazine, sulphadiazine, sulphadimidine, sulphaguanidine, sulphaurea, capreomycin, metronidazole, tinidazole, cinoxacin, ciprofloxacin, norfloxacin, nitrofurantoin, hexamine, streptomycin, carbenicillin, colistimethate, polymyxin B, furazolidone, nalidixic acid, trimethoprim-sulphamethoxazole, clindamycin, lincomycin, cycloserine, isoniazid, ethambutol, ethionamide, pyrazinamide, meropenem and imipenem. 8. A method according to claim 6 wherein the antifungal agent is selected from miconazole, ketoconazole, itraconazole, fluconazole, amphotericin, flucytosine, griseofulvin, natamycin and nystatin. 9. A method according to claim 6 wherein the antiviral agent is selected from acyclovir, AZT, ddI, amantadine hydrochloride, inosine pranobex and vidarabine. 10. A method according to claim 5 wherein the antimicrobial agent is administered locally to the patient at the site of the wound. 11. A method according to claim 1 further comprising administering an analgesic agent or an anesthetic agent locally to the patient at the site of the wound. 12. A method according to claim 11 wherein the analgesic agent is selected from methylsalicylate, salicylic acid, dyclonine and aloe vera. 13. A method according to claim 11 wherein the anesthetic is selected from benzocaine, lidocaine, xylocalne and butamben picrate. 14. A method according to claim 1 wherein the wound is an external wound. 15. A method according to claim 1 wherein said administering further comprises administering to the patient one or more of an antimicrobial agent, analgesic agent, and anesthetic agent. 16. A method according to claim 15 wherein said administering of (i) the PGE or agonist thereof, and (ii) GMCSF or derivative thereof, is carried out simultaneously with said administering of one or more of the antimicrobial agent, analgesic agent, and anesthetic agent. 17. A method according to claim 1 wherein the wound dressing or bandage further comprises an antimicrobial agent, analgesic agent, or anesthetic agent.

Details for Patent 8,273,712

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2025-11-26
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2025-11-26